May 18, 2026
Tiffany Westrich-Robertson, EACH/PIC Coalition founder and person living with an autoimmune condition, issued the following statement on the Maryland Prescription Drug Affordability Board vote on implementing an upper payment limit for Ozempic:
“The Maryland PDAB decision to establish a UPL for Ozempic is unlikely to meaningfully lower patient out-of-pocket costs and could ultimately make access to Ozempic more difficult for the people who rely on it.
“This decision was driven primarily by concerns about healthcare system spending, not evidence that Ozempic itself is creating affordability hardships for patients. Yet, it is patients who could face the consequences through new insurance barriers such as formulary changes, adverse tiering, and expanded utilization management.
“Patients need reforms that directly reduce out-of-pocket costs and protect access to the medication that works for them, not policies that may create new barriers to care without guaranteeing meaningful savings for patients.”
For more information, please visit our website to review the results from version 2.0 of our Patient Experience Survey: Prescription Drug Affordability and Unaffordability, an updated, patient-led analysis of how people actually experience affordability in their daily lives.
###
The Ensuring Access through Collaborative Health (EACH) and Patient Inclusion Council (PIC) is a two-part coalition that unites patient organizations and allied groups (EACH), as well as patients and caregivers (PIC), to advocate for drug affordability policies that benefit patients.